Survival of young women with breast cancer in a colombian referral cancer center between 2007-2016.
Supervivencia de mujeres jóvenes con cáncer de mama en el Instituto de Cancerología Las Américas entre 2007 y 2016.
Article Sidebar
PDF (Español (España))
FLIP
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Main Article Content
Background. The incidence of breast cancer in young women in Latin America is about 20%, and in Colombia, it is around 10% to 24%. Its aggressive behavior is likely due to advance stages at diagnosis and a major frequency of triple negative and Her2-positive subtypes. Objective. This study describes the overall survival (OS) of women ≤40 years old with infiltrating breast cancer that underwent breast surgery between 2007-2016 at the Institute de Cancerología Las Américas auna (Medellín-Colombia). Materials and methods: This is a retrospective observational study. We performed a survival analysis using the Kaplan-Meier method and compared the survival curves using the Log-Rank test. We calculated OS from the date of diagnosis of breast cancer to the date of the last clinic visit or date of death. We compared our results to those reported by other countries in the literature. Results. Of 4059 women who underwent breast surgery, 390 (9.6%) were ≤40 years-old, and 365 patients met inclusion criteria. At diagnosis 67 patients (18.3%) were stage I, 152 (41.6%) stage II, 140 (38.3%) stage III and 6 (1.6%) stage IV. According to the molecular intrinsic subtypes 87 (24.1%) were Luminal A, 152 (42.1%) Luminal B Her2-negative, 72 (19.9%) Luminal B Her2-positive, 17 (4.7%) Her2-enriched and 33 (9.1%) Triple Negative. Loco-regional relapse was seen in 34 patients (9.3%) and 132 (36.2%) developed systemic disease. The median OS time was 60 months (range: 8-142 months), with an OS of 81.3% (IC95%: 76.3-85.4). Patients who had Triple Negative disease had the lowest 5-year OS (67.7%, IC95%: 48-81.3). Conclusions. Patient characteristics differ from what is reported in other countries, in the higher percentage of patients with Luminal B and Her2-positive tumors and the lower proportion of Triple Negative tumors. The OS according to the cancer staging and the molecular subtypes was similar to other countries.
Downloads
Article Details
Villarreal C, Aguila C, Magallanes MC, Mohar A, Bargalló E, Meneses A, et al. Breast Cancer in young women in Latin America: an unmet, growing burden. The Oncologist [Internet] 2013; 18:26-34. https://doi.org/10.1634/theoncologist.2013-0321
Partridge AH, Ruddy KJ, Kennedy J, Winer EP. Model Program to improve care for a unique cancer population: young women with Breast Cancer. J Oncol Pract [Internet] 2012;8(5):e105-10. https://dx.doi.org/10.1200%2FJOP.2011.000501
Uribe C, Serrano M, Montañez G. Incidencia de cáncer de mama en mujeres menores de 40 años en el área metropolitana de Bucaramanga. Med UNAB [Internet] 2019;13(2):17-20. https://bit.ly/3mrLYGp
Bleyer A, O’Leary M, Barr R, Ries LAG (eds.). Cancer epidemiology in older adolescents and young adults 15 to 29 years of Age, including SEER incidence and survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006.
Ribnikar D, Ratosa I, Perhavec A, Amir E. General Overview and treatment recommendations for young women with Breast Cancer. Rev Inves Clin [Internet] 2017; 69:77-93. https://doi.org/10.24875/ric.17002175
Han W, Kim SW, Park AI, Kang D, Kim S-W, Youn Y-K, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer [Internet] 2004; 4:82. https://doi.org/10.1186/1471-2407-4-82
Murphy, B, Day, C, Hoskin, T, Habermann, E, Boughey J. Adolescents and young adults with breast cancer have more aggressive disease and treatment than patients in their forties. Ann Surg Oncol [Internet] 2019; Nov;26(12):3920-3930. https://doi.org/10.1245/s10434-019-07653-9
Wolff AC, Hammond MEH, Allison K, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologist Clinical Practice Guidelines focused update. Arch Pathol Lab Med [Internet] 2018;142(11):1362-1364. https://doi.org/10.1200/jco.2018.77.8738
Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast [Internet] 2012; 21(1):50-7. https://doi.org/10.1016/j.breast.2011.07.008
Robles J, Ruvalcaba E, Maffuz A, Rodríguez S. Breast cancer in Mexican women under 40. Ginecol Obstet Mex 2011;79(8): 482-8. PMID: 21966845
Gómez R, Ossa CA, Montoya ME, Echeverri C, Ángel G, Ascuntar J, et al. Impact of inmunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy. Ecancermedicalsciencie [Internet] 2015; 9: 562. https://dx.doi.org/10.3332%2Fecancer.2015.562
Quirós JL, Arce IS, Ramírez B. Cáncer de mama en mujeres jóvenes características clínicas y patológicas. Rev Med Univ Costa Rica [Internet] 2006;4(2):54-64. https://doi.org/10.15517/rmu.v4i2.7881
Vallejos C, Gómez HL, Abugattas JE, Marcelo MJ, Doimi FF, Neciosup SP, et al. Clinicpathologic, molecular subtype, and survival prognostic features in premenopausal breast cancer patients by age at diagnosis. ASCO Meeting Abstracts [Internet] 2010;28(suppl 15):653. https://doi.org/10.1200/jco.2010.28.15_suppl.653
Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis [Internet] 2013;5(Suppl 1): S2-8. https://doi.org/10.3978/j.issn.2072-1439.2013.05.24
Piñeros M, Sánchez R, Perry F, García OA, Ocampo R, Cendales R. Demoras en el diagnóstico y tratamiento de mujeres con cáncer de mama en Bogotá, Colombia. Salud Pública México [Internet] 2011;53(6):478-85. https://www.redalyc.org/articulo.oa?id=10621567003
Johnson RH, Chien FL, Bleyer A. Incidence of Breast Cancer with distant involvement among women in the United States, 1976 to 2009. JAMA [Internet] 2013;309(8):800-5. https://doi.org/10.1001/jama.2013.776
Paluch S, Pagani O, Partridge AH, Bar-Meir E, Fallowfield L, Fenlon D, et al. Second International Consensus Guidelines for Breast Cancer in young women (BCY2). The Breast [Internet] 2016; 26:87-99. https://doi.org/10.1016/j.breast.2015.12.010
Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, et al. The European Society of Breast Cancer Specialists Recommendations for the Management of Young Women with Breast Cancer. Eur J Cancer [Internet] 2012;48(18):3355-77. https://doi.org/10.1016/j.ejca.2012.10.004
Paluch S, Pagani O, Partridge AH, Abulkhair O, Cardoso M-J, Dent RA, et al. ESO-ESMO 3rd International Consensus Guidelines for Breast Cancer in Young Women (BCY3). The Breast [Internet] 2017; 35:203-17. https://doi.org/10.1016/j.breast.2017.07.017
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol [Internet] 2018;19(1):27-39. https://doi.org/10.1016/S1470-2045(17)30777-5
Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer [Internet] 2001;92(10):2523-8. https://doi.org/10.1002/1097-0142(20011115)92:10%3C2523::aid-cncr1603%3E3.0.co;2-6
Nixon, A, Neuberg, D, Daniel, H, Gelman, R. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. Journal of Clinical Oncology [Internet] 1994;12(5):888-94. https://doi.org/10.1200/jco.1994.12.5.888
Romero, J, Angarita, M, Burbano, R. Tamizaje del cáncer de seno de acuerdo a la experiencia médica. Rev Colomb Cirugía 2014;18(1).
